Other Content > FDA approves Exelon®Patch

Today, the Food and Drug Administration approved the Exelon Patch (rivastigmine transdermal system), the first and only skin patch for the treatment of mild to moderate Parkinson’s disease dementia and mild to moderate Alzheimer’s disease in the U.S. As you know, Parkinson's disease dementia is a distinct and common disorder, characterized by impairments in executive function, memory retrieval, and attention, in patients with an established diagnosis of Parkinson’s disease for at least two years. Two out of five people with Parkinson’s disease are estimated to have Parkinson’s disease dementia.

Exelon Patch Benefits:
Download a PDF of the full press release from Novartis.

Click for a printer friendly version